



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/007,275	10/26/2001	Timo Kars van den Berg	080743-235-001	5284

7590 01/30/2003

Ronald A. Sandler
Jones, Day, Reavis & Pogue
77 West Wacker Drive
Chicago, IL 60540

EXAMINER

YAEN, CHRISTOPHER H

ART UNIT	PAPER NUMBER
1642	6

DATE MAILED: 01/30/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/007,275	BERG ET AL.	
	Examiner	Art Unit	
	Christopher H Yaen	1642	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 01 November 2002.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-14 is/are pending in the application.
- 4a) Of the above claim(s) 1-14 is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-10 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) The translation of the foreign language provisional application has been received.
- 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- | | |
|---|--|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ . |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Election/Restrictions

1. Applicant's election without traverse of group I in Paper No. 5 is acknowledged.
2. Claims 11-14 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected inventions, there being no allowable generic or linking claim. Election was made **without** traverse in Paper No. 5. Applicant is reminded to cancel all non-elected claims.
3. Claims 1-10 are pending, claims 11-14 are withdrawn from consideration as being drawn to a non-elected invention and claims 1-10 are examined on the merits.

Claim Rejections - 35 USC § 112, 2nd paragraph

4. Claims 1-10 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
5. Regarding claims reciting the phrase "inhibiting cell functioning" or " inhibits the function", it is unclear as to which function is intended to be interfered with, as such the metes and bounds of the term cannot be determined.
6. Regarding claims reciting the term "drug", there are man type of drugs that can be encompassed by the limitations of the claims and as such renders the claim open to interpretation,
7. Regarding claims reciting the term "substance", it is unclear as to what type of substance is being referred. There are potentially many type of "substances" that can

be encompassed by the term, as such the metes and bounds of the term cannot be determined.

8. Regarding claims reciting the phrase "at least 10", it is unclear as to the degree encompassed by the phrase, for example is 2X at least 10?

9. Claim 9 and 10 provide for the use of substance, but, since the claim does not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. A claim is indefinite where it merely recites a use without any active, positive steps delimiting how this use is actually practiced.

10. Claim 9 and 10 are rejected under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under 35 U.S.C. 101. See for example *Ex parte Dunki*, 153 USPQ 678 (Bd.App. 1967) and *Clinical Products, Ltd. v. Brenner*, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966).

Claim Rejections - 35 USC § 112,1stparagraph

11. Claims 8 and 10 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. Claim 8 and 10 recite specific antibody terms. As such, these terms are considered laboratory designated terms and one of skill in the art would be unable to distinguish these antibodies from another antibody or peptide fragment that is named in the same manner.

It is apparent that the recited antibodies are required to practice the claimed invention, because they are specifically required in the claims. As required elements they must be known and readily available to the public or obtainable by a repeatable method set forth in the specification, or otherwise readily available to the public. If it is not so obtainable or available, the enablement requirements of 35 U.S.C. § 112, first paragraph, may be satisfied by a deposit of the cell lines listed in claim 7. See 37 CFR 1.802.

The specification does not provide a repeatable method for obtaining the antibodies of claims 8 and 10, and they do not appear to be readily available material. Deposit of the cell lines/hybridoma would satisfy the enablement requirements of 35 U.S.C. 112.

If a deposit is made under the terms of the Budapest Treaty, then an affidavit or declaration by applicants or someone associated with the patent owner who is in a position to make such assurances, or a statement by an attorney of record over his or her signature, stating that the deposit has been made under the terms of the Budapest Treaty and that all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed upon the granting of a patent, would satisfy the deposit requirements. See 37 CFR 1.808.

If a deposit is not made under the terms of the Budapest Treaty, then an affidavit or declaration by applicants or someone associated with the patent owner who is in a position to make such assurances, or a statement by an attorney of record over his or

Art Unit: 1642

her signature, stating that the deposit has been made at an acceptable depository and that the following criteria have been met:

- (a) during the pendency of this application, access to the invention will be afforded to one determined by the Commissioner to be entitled thereto;
- (b) all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed upon granting of the patent;
- (c) the deposit will be maintained for a term of at least thirty (30) years and at least five (5) years after the most recent request for the furnishing of a sample of the deposited material;
- (d) a viability statement in accordance with the provisions of 37 CFR 1.807; and
- (e) the deposit will be replaced should it become necessary due to inviability, contamination or loss of capability to function in the manner described in the specification.

In addition the identifying information set forth in 37 CFR 1.809(d) should be added to the specification. See 37 CFR 1.803 - 37 CFR 1.809 for additional explanation of these requirements.

Claim Rejections - 35 USC § 112,1stparagraph

12. Claims 1-10 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a method of inhibiting NO production, phagocytosis, and division of macrophage cells in vitro, with an Fab antibody fragment of ED9 and ED17, wherein the suppression of NO production is at inhibited by at least a factor of 10, and the inhibition of phagocytosis and division are suppressed by a factor of 2, does not reasonably provide enablement for a method of inhibiting cell functioning,

comprising the administration of a drug that comprising a substance that recognizes SIRP . The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims.

The first paragraph of 35 U.S.C. 112 states, "The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same...". The courts have interpreted this to mean that the specification must enable one skilled in the art to make and use the invention without undue experimentation. The courts have further interpreted undue experimentation as requiring "ingenuity beyond that to be expected of one of ordinary skill in the art" (Fields v. Conover, 170 USPQ 276 (CCPA 1971)) or requiring an extended period of experimentation in the absence of sufficient direction or guidance (In re Colianni, 195 USPQ 150 (CCPA 1977)). Factors to be considered in determining whether a disclosure meets the enablement requirement of 35 U.S.C. 112, first paragraph, have been described in In re Colianni, 195 USPQ 150, 153 (CCPA 1977) and have been clarified by the Board of Patent Appeals and Interferences in Ex parte Forman, 230 USPQ 546 (BPAI 1986). Among the factors are the nature of the invention, the state of the prior art, the predictability or lack thereof in the art, the amount of direction or guidance present, the presence or absence of working examples, the breadth of the claims, and the quantity of experimentation needed.

The nature of the invention: The invention is drawn to a method of inhibiting cell functions comprising the administration of a drug comprising a substance that binds to the extracellular domain of SIRP.

The amount of direction or guidance present and the presence or absence of working examples: The instant specification provides working examples which are drawn the role of SIRP Fab fragments in the suppression of NO production, decrease phagocytosis, and decrease cellular division. However, nowhere in the specification does it teach how to inhibit all type of cellular functions associated with anti-inflammatory or anti-cancer using any drug or for that matter any antibody against SIRP. The specification specifically teaches that whole antibodies to SIRP where ineffective in inhibiting NO production, decrease phagocytosis, and decrease cellular division, but instead induced NO production, phagocytosis, and cellular division. Because only two specific Fabs are provided in the specification, it does not enable the method for all types of drugs that comprise substances capable of binding to the extracellular domain of SIRP, nor does it provide for any (bio)chemically modified products of these Fab fragments. Furthermore, the specification has only taught the ability of the Fab fragments to function in an in vitro culture system. There is no disclosure that would teach one of skill in the art how to use the method in an in vivo system. There is no indication that the Fab fragments themselves would not elicit an immune response, the dosages required to effect the method nor has there been any indication that the method is even able to inhibit the same cellular functions tested for in vitro. Therefore, the specification has only enabled to one of skill in the art a method of inhibiting the

Art Unit: 1642

cellular functions of NO production, decrease phagocytosis, and decrease cellular division in an in vitro system, wherein antibody fragments derived from ED9 and ED17 are used to inhibit the said cellular functions.

The breadth of the claims and the quantity of experimentation needed: Given the broad range of drugs and cellular functions encompassed by the claims, it would require undue experimentation by one of skill in the art to be able to practice the invention commensurate in scope with the claims.

Conclusion

No claims are allowed. The closest prior art found was Lienard H et al (J Biol Chem 1999 Nov 5;274(45):32493-9) wherein they disclose the role of SIRP in cell proliferation and also in ITEM cell activation.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher H Yaen whose telephone number is 703-305-3586. The examiner can normally be reached on Monday-Friday 9-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa can be reached on 703-308-3995. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-305-3014 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Christopher Yaen
Art Unit 1642
January 27, 2003



ALI R. SALIMI
PRIMARY EXAMINER